Royal Bank of Canada
KPTI icon

Royal Bank of Canada’s Karyopharm Therapeutics KPTI Stock Holding History

Royal Bank of Canada’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,667
Closed -$530K – 6519
2015
Q4 		$530K Buy
+2,667
New +$577K ﹤0.01% 3720

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Royal Bank of Canada's KPTI Position: Q1 2026 in Review

Royal Bank of Canada increased its Karyopharm Therapeutics (KPTI) stake by 4.1% in Q1 2026, buying an estimated $18.3K and bringing the position to 60,399 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #4401.

Royal Bank of Canada first reported a position in KPTI in Q2 2014 and has held it in 47 quarters since. The position peaked at $824K in Q2 2014. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Royal Bank of Canada held 60,399 shares of Karyopharm Therapeutics worth $336K as of Q1 2026.
  • Royal Bank of Canada bought 2,399 Karyopharm Therapeutics shares in Q1 2026, an estimated $18.3K.
  • Karyopharm Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4401 holding.
  • Royal Bank of Canada first reported a position in Karyopharm Therapeutics in Q2 2014 and has held it in 47 quarters since.
  • Royal Bank of Canada's Karyopharm Therapeutics position peaked at $824K in Q2 2014.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.